Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Executive Summary
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
You may also be interested in...
Asia Deal Watch: CStone Partners With LegoChem On Novel ADC Candidate
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Catch It While You Can: Smaller Firms Flock To China As Value Takes Center Stage
Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
Need a specific report? 1000+ reports available
Buy Reports